Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The user experiencing diffuse hair loss is using various treatments including RU58841, finasteride, minoxidil with tretinoin, anti-hair loss shampoo, and microneedling, and is considering adding peptides TB500, BPC157, and GHK-Cu. They have low growth hormone levels and are questioning its impact on hair loss, while another user suggests androgenic alopecia and androgens are likely the main cause of hair loss.

Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.

Treatment for hair loss, including Pyrilutamide, Minoxidil, Finasteride, and RU58841; with some users reporting success in growing vellus hairs.

Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.

The effectiveness of pyrilutamide, a hair loss treatment, with research results being postponed until September. Various people shared their experiences with topical finasteride, minoxidil and RU58841, as well as other treatments such as dandruff shampoo, group buys and grey markets.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

The conversation is about the effectiveness of Redensyl for hair loss and whether to continue using Minoxidil alone, despite planning for a hair transplant eventually. The user also mentions using dermarolling, PRP therapy, and Nutrafol.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

A user reports significantly reduced hair shedding by using a topical mixture containing 10% Minoxidil, 0.1% Melatonin, 5% Azelaic Acid, 5% Rosemary Oil, and 5% Peppermint Oil, and attributes the success mainly to Melatonin. They also use a copper peptide serum (AHK-Cu) for hair growth and Ketoconazole shampoo for scalp cleaning, but have stopped using other treatments like Finasteride and RU58841.

The post and conversation discuss the effectiveness of pyrilutamide for hair loss, with comparisons to finasteride and RU58841. Users express skepticism due to failed trials and high costs, with some waiting for more data before trying pyrilutamide.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

Exosomes are being considered for hair regrowth after using finasteride and minoxidil, with skepticism about their effectiveness and high cost. Users discuss administration methods like injections and microneedling, but concerns about pricing and potential scams are prevalent.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

A product that makes hair look thicker and healthier without promoting regrowth. Discussions include treatments like minoxidil, finasteride, red light therapy, and a serum with caffeine and peptides, with mixed effectiveness opinions.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

Bryan Johnson's new hair loss product, which includes peptides, is viewed skeptically by many, with concerns it may be a money grab rather than an effective treatment. Most users prefer proven treatments like finasteride and minoxidil, which are cheaper and have established results.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

A user is considering whether to continue using RU58841 or switch to hair system patches for a receding hairline, while already using finasteride, oral minoxidil, and microneedling. Another user suggests buying RU58841 in powder form to save money and notes the original poster's hair has significantly improved.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The user experienced hair improvement over a year using finasteride, topical minoxidil, tretinoin, ketoconazole, and microneedling. The hair density and hairline have strengthened with this routine.

The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.

How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.